$ABEO
ABEONA THERAPEUTICS INC.

2024 Q4 Form 10-Q Financial Statement

#000149315224045340 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.404M
YoY Change 53.94%
% of Gross Profit
Research & Development $8.941M
YoY Change 25.08%
% of Gross Profit
Depreciation & Amortization $487.0K
YoY Change -6.35%
% of Gross Profit
Operating Expenses $15.35M
YoY Change 35.39%
Operating Profit -$15.35M
YoY Change 35.39%
Interest Expense $1.102M
YoY Change 949.52%
% of Operating Profit
Other Income/Expense, Net $145.0K
YoY Change 30.63%
Pretax Income -$30.27M
YoY Change 155.65%
Income Tax
% Of Pretax Income
Net Earnings -$30.27M
YoY Change 155.74%
Net Earnings / Revenue
Basic Earnings Per Share -$0.63
Diluted Earnings Per Share -$0.63
COMMON SHARES
Basic Shares Outstanding 43.47M shares 43.31M shares
Diluted Shares Outstanding 48.08M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $109.7M
YoY Change 103.91%
Cash & Equivalents $15.73M
Short-Term Investments $93.98M
Other Short-Term Assets $1.343M
YoY Change 3.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables $1.613M
Total Short-Term Assets $112.7M
YoY Change 96.73%
LONG-TERM ASSETS
Property, Plant & Equipment $4.058M
YoY Change 1.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $88.00K
YoY Change -12.0%
Total Long-Term Assets $7.935M
YoY Change -10.06%
TOTAL ASSETS
Total Short-Term Assets $112.7M
Total Long-Term Assets $7.935M
Total Assets $120.6M
YoY Change 82.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.789M
YoY Change 7.6%
Accrued Expenses $5.210M
YoY Change 31.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $4.444M
YoY Change
Total Short-Term Liabilities $18.42M
YoY Change 119.0%
LONG-TERM LIABILITIES
Long-Term Debt $14.21M
YoY Change
Other Long-Term Liabilities $42.19M
YoY Change 18.51%
Total Long-Term Liabilities $14.21M
YoY Change -60.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.42M
Total Long-Term Liabilities $14.21M
Total Liabilities $74.82M
YoY Change 69.85%
SHAREHOLDERS EQUITY
Retained Earnings -$804.0M
YoY Change 9.7%
Common Stock $434.0K
YoY Change 75.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $45.77M
YoY Change
Total Liabilities & Shareholders Equity $120.6M
YoY Change 82.47%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$30.27M
YoY Change 155.74%
Depreciation, Depletion And Amortization $487.0K
YoY Change -6.35%
Cash From Operating Activities -$12.23M
YoY Change 113.14%
INVESTING ACTIVITIES
Capital Expenditures $404.0K
YoY Change 910.0%
Acquisitions
YoY Change
Other Investing Activities -$5.763M
YoY Change -69.18%
Cash From Investing Activities -$6.167M
YoY Change -67.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -299.0K
YoY Change -101.3%
NET CHANGE
Cash From Operating Activities -12.23M
Cash From Investing Activities -6.167M
Cash From Financing Activities -299.0K
Net Change In Cash -18.70M
YoY Change 1146.67%
FREE CASH FLOW
Cash From Operating Activities -$12.23M
Capital Expenditures $404.0K
Free Cash Flow -$12.64M
YoY Change 118.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Royalty Expense
RoyaltyExpense
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-15771
dei Entity Registrant Name
EntityRegistrantName
ABEONA THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-0221517
dei Entity Address Address Line1
EntityAddressAddressLine1
6555 Carnegie Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
4thFloor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cleveland
dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
44103
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
813-4701
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
ABEO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3789000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
88000 usd
CY2024Q3 us-gaap Assets
Assets
120592000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2789000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5210000 usd
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 ABEO Warrant Liabilities
WarrantLiabilities
38789000 usd
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43471030 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15726000 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
93975000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
338000 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1613000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1005000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
112657000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4058000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3533000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4455000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
277000 usd
CY2023Q4 us-gaap Assets
Assets
64002000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1858000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5985000 usd
CY2023Q4 ABEO Warrant Liabilities
WarrantLiabilities
31352000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
74819000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
49176000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43404706 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43404706 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
434000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
265000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
849388000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
764151000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-803965000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-749524000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-84000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-66000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
45773000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
14826000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120592000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64002000 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000318306
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
998000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13422000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4402000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
37753000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
729000 usd
CY2023Q4 ABEO Due To Licensor
DueToLicensor
4580000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24797564 shares
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
50000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1840000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
18000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
146527000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
90233000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
426000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-200000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-941000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39456000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58116000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9962000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-189000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14811000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-831000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q3 us-gaap Royalty Expense
RoyaltyExpense
usd
CY2024Q3 ABEO Gain Loss On Rightofuse Lease Assets
GainLossOnRightofuseLeaseAssets
usd
CY2023Q3 ABEO Gain Loss On Rightofuse Lease Assets
GainLossOnRightofuseLeaseAssets
usd
ABEO Gain Loss On Rightofuse Lease Assets
GainLossOnRightofuseLeaseAssets
usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
ABEO Stock Issued During Period Value Of Common Stock Upon Exercise Of Prefunded Warrants Net Of Shares Settled
StockIssuedDuringPeriodValueOfCommonStockUponExerciseOfPrefundedWarrantsNetOfSharesSettled
usd
ABEO Gain Loss Of Rightofuse Lease Assets
GainLossOfRightofuseLeaseAssets
usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
ABEO Proceeds From Underwritten Sales Of Common Stock Net Of Issuance Costs
ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts
usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
ABEO Rightofuse Lease Assets Obtained From New Operating Lease Liabilities
RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities
usd
ABEO Derivative And Warrant Additions Associated With Loan And Security Agreement
DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement
usd
ABEO Reclassification Of Derivative Liability To Equity
ReclassificationOfDerivativeLiabilityToEquity
usd
ABEO Changes In Accrued Property And Equipment
ChangesInAccruedPropertyAndEquipment
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
usd
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
usd
CY2023Q4 ABEO Accreted Final Payment Fee
AccretedFinalPaymentFee
usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14473000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
338000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2444000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
55737000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
4444000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1057000 usd
CY2024Q3 ABEO Due To Licensor
DueToLicensor
4921000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18422000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3402000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14206000 usd
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26523878 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26523878 shares
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3500000 usd
CY2023Q3 us-gaap Royalty Expense
RoyaltyExpense
30000 usd
us-gaap Royalty Expense
RoyaltyExpense
1605000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8941000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7148000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25366000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23712000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6404000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4156000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22173000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13174000 usd
ABEO Gain Loss On Rightofuse Lease Assets
GainLossOnRightofuseLeaseAssets
1065000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
15345000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
11334000 usd
us-gaap Operating Expenses
OperatingExpenses
47539000 usd
us-gaap Operating Expenses
OperatingExpenses
37426000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15345000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11334000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-47539000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-33926000 usd
CY2024Q3 us-gaap Interest Income Operating
InterestIncomeOperating
1189000 usd
CY2023Q3 us-gaap Interest Income Operating
InterestIncomeOperating
593000 usd
us-gaap Interest Income Operating
InterestIncomeOperating
3223000 usd
us-gaap Interest Income Operating
InterestIncomeOperating
1374000 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
1102000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
105000 usd
us-gaap Interest Expense
InterestExpense
3126000 usd
us-gaap Interest Expense
InterestExpense
309000 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
15156000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1101000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7530000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7465000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
145000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
111000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
531000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2729000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-30269000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11836000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54441000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37597000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48081758 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48081758 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24797564 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38504273 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38504273 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19942613 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19942613 shares
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-33000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-18000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
29000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
29000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30219000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11840000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54459000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37567000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
73241000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1804000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-188000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1135000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-30269000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
50000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
45773000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
14826000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4673000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-517000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
9962000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
70153000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1135000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54441000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
45773000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
9345000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1557000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-4000 usd
CY2023Q3 ABEO Stock Issued During Period Value Net Of Offering Costs Under Direct Placement Offering
StockIssuedDuringPeriodValueNetOfOfferingCostsUnderDirectPlacementOffering
22980000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11836000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
22038000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26761000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26761000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3254000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-13000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6623000 usd
ABEO Stock Issued During Period Value Net Of Offering Costs Under Direct Placement Offering
StockIssuedDuringPeriodValueNetOfOfferingCostsUnderDirectPlacementOffering
22980000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37597000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
22038000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
22038000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54441000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37597000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1465000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1797000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4673000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3254000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7530000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7465000 usd
ABEO Gain Loss Of Rightofuse Lease Assets
GainLossOfRightofuseLeaseAssets
1065000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-54000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-134000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
666000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
680000 usd
us-gaap Noncash Contribution Expense
NoncashContributionExpense
1146000 usd
us-gaap Noncash Contribution Expense
NoncashContributionExpense
309000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-52000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-831000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2021000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
539000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-189000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
96000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
762000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-904000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-5000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27774000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
294000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
187000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
48219000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
37005000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11321000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6623000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
22980000 usd
ABEO Proceeds From Repayment Settlement Of Restricted Share Awards
ProceedsFromRepaymentSettlementOfRestrictedShareAwards
-327000 usd
ABEO Proceeds From Repayment Settlement Of Restricted Share Awards
ProceedsFromRepaymentSettlementOfRestrictedShareAwards
-13000 usd
ABEO Proceeds From Underwritten Sales Of Common Stock Net Of Issuance Costs
ProceedsFromUnderwrittenSalesOfCommonStockNetOfIssuanceCosts
70153000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
20000000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
963000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
98825000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29590000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1253000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9505000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14555000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16064000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5050000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15726000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4712000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
338000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
338000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16064000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5050000 usd
ABEO Rightofuse Lease Assets Obtained From New Operating Lease Liabilities
RightofuseLeaseAssetsObtainedFromNewOperatingLeaseLiabilities
419000 usd
ABEO Derivative And Warrant Additions Associated With Loan And Security Agreement
DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement
1042000 usd
ABEO Reclassification Of Derivative Liability To Equity
ReclassificationOfDerivativeLiabilityToEquity
1135000 usd
ABEO Changes In Accrued Property And Equipment
ChangesInAccruedPropertyAndEquipment
166000 usd
us-gaap Interest Paid Net
InterestPaidNet
1980000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
7000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
7000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54400000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37600000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-804000000.0 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
110000000.0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zVOpl99hO1W6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Other Receivables
OtherReceivables
1600000 usd
CY2023Q4 us-gaap Other Receivables
OtherReceivables
2100000 usd
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0001
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14047363 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14047363 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11930126 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11930126 shares
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
94059000 usd
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
51000 usd
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
135000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
93975000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37819000 usd
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
66000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37753000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18499000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16524000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14441000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12991000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4058000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3533000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1500000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1800000 usd
CY2023Q4 ABEO Warrant Liabilities
WarrantLiabilities
31352000 usd
ABEO Fair Value Adjustment Of Warrants Issued
FairValueAdjustmentOfWarrantsIssued
220000 usd
ABEO Gain Loss Recognized In Earnings From Change In Fair Value
GainLossRecognizedInEarningsFromChangeInFairValue
7217000 usd
CY2024Q3 ABEO Warrant Liabilities
WarrantLiabilities
38789000 usd
ABEO Fair Value Of Derivatives Issued
FairValueOfDerivativesIssued
822000 usd
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
313000 usd
ABEO Reclassification Of Derivative Liablity In Connection With Loan Agreement
ReclassificationOfDerivativeLiablityInConnectionWithLoanAgreement
-1135000 usd
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_z6WUwGCOnXnf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_825_zw3eQkb45Ls3">SETTLEMENT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 12, 2021, the Company entered into a settlement agreement (“Settlement Agreement”) with the Company’s prior licensor REGENXBIO Inc. (“REGENXBIO”) to resolve all existing disputes between the parties. In accordance with the Settlement Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zLBwm8Na5Sg5" title="Settlement liabilities, current">30.0</span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zkkzEsDVPuO6" title="Loss contingency settlement agreement terms">(1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement (paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, the Company recorded the payable due to REGENXBIO in the condensed consolidated balance sheets based on the present value of the remaining payments due to REGENXBIO under the Settlement Agreement using an effective interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zRalwtUZMsY7">9.6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%. The present value of the amount due in November 2024 was $<span id="xdx_903_eus-gaap--LongTermDebt_iI_pn5n6_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zauI5rfSGzXf">4.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zDLmB5mRYDvg">4.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of September 30, 2024 and December 31, 2023, respectively. On November 13, 2024, the Company subsequently paid the remaining $<span id="xdx_90D_eus-gaap--LongTermDebt_iI_pn5n6_c20241113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zARFijua9lFk" title="Long term debt">5.0</span> million amount due per the Settlement Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3736000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38504273 shares
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3688000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1474000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2297000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5210000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5985000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1057000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
998000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3402000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4402000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4459000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5400000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
312000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
340000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
974000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1048000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
96000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
66000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
292000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
281000 usd
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000 usd
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
19000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
42000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
50000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
416000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
425000 usd
us-gaap Lease Cost
LeaseCost
1308000 usd
us-gaap Lease Cost
LeaseCost
1379000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
450000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
853000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
791000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
807000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
823000 usd
CY2024Q3 ABEO Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1693000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5417000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
958000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4459000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P61M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.071 pure
CY2024Q3 ABEO Future Cash Receipts From Operating Sublease Remainder Of Fiscal Year
FutureCashReceiptsFromOperatingSubleaseRemainderOfFiscalYear
160000 usd
CY2024Q3 ABEO Future Cash Receipts From Operating Sublease Next Twelve Months
FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths
485000 usd
CY2024Q3 ABEO Future Cash Receipts From Operating Sublease
FutureCashReceiptsFromOperatingSublease
645000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000 usd
CY2024Q3 ABEO Accreted Final Payment Fee
AccretedFinalPaymentFee
255000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1605000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
18650000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
4444000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14206000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6667000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8889000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4444000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000 usd
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1788000 shares
CY2021Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.75
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1788000 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.75
CY2021Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
16000000.0 usd
CY2021Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1500000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7000000.0 usd
CY2021Q4 ABEO Fair Value Warrant Liabilities
FairValueWarrantLiabilities
9000000.0 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1804000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1557000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4673000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3254000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
179001 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.58
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M29D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1863 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
34.45
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
177138 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M2D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
157029 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
38.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M26D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5000 usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
20109 shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
36.35
ABEO Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1
P6Y9M29D
CY2024Q3 ABEO Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1
3000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13100000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y3M18D
ABEO Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue
4500000 usd

Files In Submission

Name View Source Status
0001493152-24-045340-index-headers.html Edgar Link pending
0001493152-24-045340-index.html Edgar Link pending
0001493152-24-045340.txt Edgar Link pending
0001493152-24-045340-xbrl.zip Edgar Link pending
abeo-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
abeo-20240930_lab.xml Edgar Link unprocessable
abeo-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
abeo-20240930_cal.xml Edgar Link unprocessable
abeo-20240930_def.xml Edgar Link unprocessable